The Latest in Aggressive Lymphomas

Brentuximab vendotin plus CHP meets PFS endpoint in ECHELON-2

October 2, 2018

FDA lifts partial hold on tazemetostat trials

September 30, 2018

Prognostic factors guide mantle cell treatment decisions

September 28, 2018

CAR T-cell studies dominate ongoing cellular therapy trials

September 26, 2018

Outpatient lenalidomide/rituximab yields long-term MCL remission

September 25, 2018

NICE looks likely to reject use of Kymriah for DLBCL

September 24, 2018

Best practices defined for proton therapy in mediastinal lymphomas

September 18, 2018

Aggressive Lymphomas

Venetoclax label now includes MRD data

September 12, 2018

TP53 mutation plus complex karyotype equals poor prognosis

September 10, 2018

Novartis nabs first CAR T approval in Canada

September 7, 2018

RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients

September 6, 2018

England green-lights coverage of one CAR T-cell therapy

September 6, 2018

Researchers find drug target in anaplastic large-cell lymphoma

September 6, 2018

Adverse events outweigh promise of SGN-CD70A against NHL

August 30, 2018

New BTK inhibitor under review in China

August 29, 2018